Stopped: Interim analysis showing safety concerns
This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind, single-center trial.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Absolute and relative change in sodium excretion rate.
Timeframe: After 24 hours and at termination of treatment (up to 48 hours)
Absolute and relative change in urine volume.
Timeframe: After 24 hours and at termination of treatment (up to 48 hours)
Change of absolute body weight.
Timeframe: At termination of treatment (up to 48 hours)